Project description:Prostate cancer (PCa) is one of the most prevalent malignancies in men and remains a major cause of cancer-related mortality worldwide. While taxane-based chemotherapies, such as docetaxel, are standard treatment options for metastatic castration-resistant prostate cancer (mCRPC), their long-term efficacy is limited. This highlights an urgent need for new therapeutic targets and more effective treatment strategies to improve survival in advanced PCa. Here, we show that CHD1L is overexpressed in prostate cancer tissues and correlates with poor prognosis. Knockdown of CHD1L substantially inhibits PCa cell proliferation and induces apoptosis. Moreover, inhibition of CHD1L by the small molecule OTI-611 significantly suppresses PCa cell proliferation, migration, and invasion, and induces apoptosis both in vitro and in vivo. Mechanistically, inhibition of CHD1L induces the expression of FOXO3 (a classic transcription factor) and its downstream target PUMA (a key apoptosis inducer). Restricting the expression of FOXO3 substantially reverses the anti-tumor effects induced by OTI-611. Furthermore, OTI-611 synergizes with docetaxel to enhance apoptotic cell death, providing a promising strategy to overcome docetaxel resistance. These findings highlight the therapeutic potential of targeting CHD1L in combination with existing treatments, offering a novel approach for the treatment of advanced prostate cancer.
Project description:Analysis of SCC-15 tongue cancer cells overexpressing miR-611. miR-611 is frequently upregulated in primary tongue cancer. Results provide insight into the role of miR-611 in the pathogenesis of tongue cancer. We used micorarrays to detailed the genes regulated by miR-611 in SCC-15 cells.
Project description:RNA-Seq analysis was carried out to investigate the effects of selective CDK8/19 inhibitor Senexin B and SNX631 on gene expression in LNCaP prostate cancer cells treated with or without androgen.
Project description:This is a RNA-Seq analysis aiming to study the transcriptomic changes of C4-2 prostate cancer cells induced by HSF1 inhibitor DTHIB (E12)
Project description:RNA-Seq analysis of prostate cancer cells derived from xenografts treated daily with drugs targeting androgen biosynthesis and the androgen receptor.
Project description:RNA-Seq (miRNA) analysis of prostate cancer cells derived from xenografts treated daily with drugs targeting androgen biosynthesis and the androgen receptor.
Project description:Histone deacetylase (HDAC) inibitors suppress cell proliferation of prostate cancer, but the detailed mechanisms are unknown. Moreover, HDAC includes 18 family members, namely HDAC1-11 and SIRT1-7, and differences of effects on prostate cancer proliferation among these enzymes are also unknown. Thus, we clarified differences of gene expression between prostate cancer cell line (LNCaP) treated with pan-HDAC inhibitors (TSA and OBP-801) or selective HDAC inhibitor (NCC-149, HDAC8-specific inhibitor)using cDNA microarray. LNCaP treated with TSA (1μM), NCC149 (2μM), OBP-801 (200nM) or DMSO for 24hrs, RNA was extracted from cells, and cDNA array was performed.
